Tvardi Therapeutics, trading under Nasdaq: TVRD, has experienced a notable surge in its stock price following the release of positive Phase 1 clinical trial results for its investigational drug, TTI-109.
The trial demonstrated that TTI-109 matched the exposure levels of TTI-101 while showing improved tolerability, a key factor in drug development.
Additionally, the results confirmed clear engagement with the STAT3 target, which is critical for the drug's intended therapeutic effects.